Dental laser maker Biolase Technology Inc. has announced the appointment of two veterans of business, finance and medicine to its board of directors. Dr. Alex Arrow and Dr. Norman J. Nemoy will join the board effective immediately, replacing George V. d'Arbeloff and Robert M. Anderton, who have resigned. “The addition of Alex Arrow and Norman Nemoy brings a wealth of business experience and clinical depth to the board at a time when we are reshaping the company and moving forward to return the company to expansion and profitability,” said David M. Mulder, chairman and CEO of Biolase. “It is rare to find two executives with both an understanding of medicine and how new technologies are developed and adopted, along with the management and industry background necessary to provide guidance to management and stewardship for shareholder rights and value.” Arrow has been chief financial officer of San Carlos, Calif.-based Arstasis Inc., a commercial stage medical device manufacturer, since 2007. From 2002 to 2007, he headed medical technology equity research at the global investment bank Lazard, providing research coverage on a wide variety of medical device manufacturers, including Biolase, and writing industry reports spanning the range of medical technology business segments, including the laser industry. He also spent two years as chief financial officer of the Patent & License Exchange, later renamed PLX Systems Inc., and three years as the publishing life sciences research analyst at Wedbush Morgan Securities. In 1996, he was a surgical resident at UCLA Medical Center. He received his chartered financial analyst certification in 1999. He earned a medical degree from Harvard Medical School in 1996 and a BA in biophysics, magna cum laude, from Cornell University in 1992. Nemoy is a practicing physician at Tower Urology Medical Group and is on the attending staff at both Cedars-Sinai Medical Center and Century City Medical Center. He graduated from the University of Illinois School of Medicine and obtained his urological training at Stanford University Medical Center in Palo Alto, Calif. While at Stanford, he was honored with an appointment as a US Public Health Fellow. Following his training at Stanford, he served on the clinical faculty at UCLA School of Medicine. He joined Tower Urology Medical Group in 1986. He is a fellow of the American College of Surgeons and is board certified by the American Board of Urology. He is considered an expert in advanced robotic surgery and has participated in numerous clinical studies designed to test the safety and clinical effectiveness of many new urological and other medical therapies. For more information, visit: www.biolase.com